PRTODAY / NewswireToday Free press release distribution service network

Written by / Agency / Source: AnaSpec, Inc.

Check Ads Availability|e-mail Article


Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!

AnaSpec, Inc. Introduces New SensoLyte™ Cathepsin D Activity Assay Kits - AnaSpec has introduced a new series of SensoLyte™ Cathepsin D Activity Assay Kits to address the issue of autofluorescence interference
AnaSpec, Inc. Introduces New SensoLyte™ Cathepsin D Activity Assay Kits

 

NewswireToday - /newswire/ - San Jose, CA, United States, 2008/03/07 - AnaSpec has introduced a new series of SensoLyte™ Cathepsin D Activity Assay Kits to address the issue of autofluorescence interference.

   
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Pharma/BioTech/Nutrition Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

While the detection of cathepsin activity plays a crucial role in the research of a number of pathological processes, the sensitivity of traditional cathepsin assay kits has been significantly hampered by autofluorescence interference at lower wavelengths. AnaSpec has introduced a new series of SensoLyte™ Cathepsin D Activity Assay Kits to address the issue of autofluorescence interference.

The SensoLyte™ 520 Cathepsin D Activity Assay Kit offers Cathepsin D detection at the industry’s longest wavelength. Leveraging AnaSpec’s proprietary fluorescence technology, the SensoLyte™ 520 Cathepsin D Activity Assay Kit incorporates a FRET substrate that fluoresces at a much higher wavelength than standard substrates. The higher wavelength fluorescence results in cathepsin detection that avoids autofluorescence interference from cell components and test compounds.

The FRET substrate in the SensoLyte™ 520 Cathepsin D Activity Assay Kit utilizes a unique 5-FAM/QXL™520 FRET pair (Ex/Em=490/520 nm upon cleavage). The sequence of the FRET substrate is derived from the cleavage site of Cathepsin D. In the intact FRET peptides the fluorescence of donors is quenched by acceptors. When active Cathepsin D cleaves FRET substrate into two separate fragments, the fluorescence of the donor is recovered, and can be monitored.

AnaSpec also offers the SensoLyte™ 390 Cathepsin D Activity Assay Kit that uses a traditional Mc-Ala/Dnp FRET peptide for measurement of enzyme activity (Ex/Em=330/390 nm upon cleavage)

Cathepsin is a protease that breaks apart other proteins found in many types of cells. There are at least 12 members of the cathepsin family which are distinguished by their structure and the proteins that they cleave. Cathepsin D is the lysosomal aspartic proteinase implicated in intracellular protein degradation.

About AnaSpec, Inc.
AnaSpec, Inc. (anaspec.com) is a leading provider of integrated proteomics solutions to pharmaceutical, biotech, and academic research institutions throughout the world. With a vision for innovation through synergy, AnaSpec focuses on three core technologies: peptides, detection reagents (dyes, assay kits, & antibodies), and combinatorial chemistry.

References:
1. Berchem, G. et al, Oncogene 21, 5951(2002)
2. Liaudet-Coopman, E. et al, Cancer Lett. 237, 167 (2006)
3. Davidson, Y. et al, J Neurol Neurosurg Psychiat.77, 515 (2006)
4. Laurent-Matha, V. et al, J Cell Biol. 168,489 (2005)
5. Simon, DI. et al, Biochemistry 33, 6555 (1994)
6. Baechle, D. et al, J Peptide Sci. 11, 166 (2005)
7. Yasuda, Y. et al, J Biochem. 125, 1137 (1999).

 
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Pharma/BioTech/Nutrition Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

Written by / Agency / Source: AnaSpec, Inc.

 
 

Availability: All Regions (Including Int'l)

 

Traffic Booster: [/] Quick Newswire Today Visibility Checker

 

Distribution / Indexing: [+]

 
 
# # #
 

 
  Your Banner Ad showing on ALL
Pharma/BioTech/Nutrition articles,
CATCH Visitors via Your Competitors Announcements!


AnaSpec, Inc. Introduces New SensoLyte™ Cathepsin D Activity Assay Kits

Company website links NOT available to basic submissions
It is OK to republish and/or LINK any newswire for any legitimate media purpose as long as you name Newswire Today and LINK as the source.
 
  Is this your article?
Activate ALL web links and social stream by Upgrading to Press Release PREMIUM Plan Now!

|
Publisher Contact: Ping Yang 
408-452-5055 ping[.]anaspec.com
 
Newswire Today - PRZOOM / PRTODAY disclaims any content contained in this article. If you need/wish to contact the company who published the current release, you will need to contact them - NOT us. Issuers of articles are solely responsible for the accuracy of their content. Our complete disclaimer appears here.
IMPORTANT INFORMATION: Issuance, publication or distribution of this press release in certain jurisdictions could be subject to restrictions. The recipient of this press release is responsible for using this press release and the information herein in accordance with the applicable rules and regulations in the particular jurisdiction. This press release does not constitute an offer or an offering to acquire or subscribe for any AnaSpec, Inc. securities in any jurisdiction including any other companies listed or named in this release.

Pharma/BioTech/Nutrition via RSSAdd NewswireToday - PRZOOM Headline News to FeedBurner
Find who RetweetFollow @NewswireTODAY



Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!


Read Latest Articles From AnaSpec, Inc. / Company Profile


Read Pharma/BioTech/Nutrition Most Recent Related Newswires:

Frost & Sullivan Commends Nemaura for Developing Superior Transdermal Drug Delivery Technology Platforms, the Memspatch and Micropatch
Greenphire Sponsors Second Annual Clinical Trial Agreements, Investigator Payments and Fair Market Value Meeting
Genentech’s Gazyva Helped People with Previously Untreated Follicular Lymphoma Live Significantly Longer
BD Announces Adoption of Windows 10 ‘Internet of Things’ for the Pyxis™ ES System
Greenphire Named to Deloitte 2016 Technology Fast 500™
Genentech Showcases New Clinical Data Across a Variety of Blood Diseases at American Society of Hematology 2016 Annual Meeting
BD Collaborates with JDRF to Focus on Extended Wear Innovations for Insulin Infusion Delivery
BD Launches First Syringe Designed for Use with Humulin® R U-500 Insulin
MDxHealth Announces Unique CPT Code Awarded for ConfirmMDx from the American Medical Association
BD MAX™ Vaginal Panel Receives FDA Market Authorization to Detect Most Common Causes of Vaginal Infections
Greenphire Receives EU-US Privacy Shield Certification
The 2016 Georges Mathé Prize Recognizes Research on the Immunological Determinants of the Response to Breast Cancer Treatment
MDxHealth Announces Agreement with HIFU CLINIC Prostate Cancer Center for Distribution of SelectMDx in Poland
First Patient in Malaysia Receives TheraSphere™ Radioembolisation Therapy
FDA Approves Genentech’s Lucentis® (Ranibizumab Injection) Prefilled Syringe

Boost Your Social Network
& Crowdfunding Campaigns


LIFETIME SOCIAL MEDIA WALL
NewswireToday Celebrates 10 Years in Business


PREMIUM Members


Visit  JobsWare.com

Visit  BizJobs.com





 
  ©2016 Newswire Today — Limelon Advertising, Co.
Home | About | Advertise/Pricing | Contact | Investors | Privacy/TOS | Sitemap | FRANCAIS
newswire, PR free press releases distribution service magazines engine news alert newsroom press room breaking news public relations articles company news alerts newswiredistribution ezine bizentrepreneur biznewstoday digital business report market search pr firms agencies reports distri-bution today investor relation successful internet entrepreneurs newswire distribution prtoday.com freenewswiredistribution asianewstoday bizwiretoday USA pr UK today - NOT affiliated with PRNewswire as we declined their partnership offer in 2013
 
PRTODAY & NewswireTODAY are NOT affiliated with USA TODAY (usatoday.com)